Development of a novel oral vaccine against *Mycobacterium avium paratuberculosis* and Johne disease

A patho-biotechnological approach

C. Johnston,¹ A. Coffey,¹ Jim O' Mahony^{1,*} and R.D. Sleator^{1,2}

¹Cork Institute of Technology; Bishopstown, Cork Ireland; and ²Alimentary Pharmaceutical Centre University College; Cork, Ireland

Key words: vaccine, paratuberculosis, Johne disease, patho-biotechnology, *Listeria monocytogenes*

Abbreviations: MAP, *Mycobacterium avium* subspecies *paratuberculosis*; GRAS, generally regarded as safe; FAE, follicle associated epithelium; FAP, fibronectin attachment protein; inlA, internalin A; ROI, reactive oxygen intermediates; RNI, reactive nitrogen intermediates; LLO, listeriolysin O; CTL, cytolytic T lymphocytes; CD4⁺, cluster of differentiation 4; CD8⁺, cluster of differentiation 8; Th1, T helper 1; Th2, T helper 2; IFN γ , interferon gamma; TNF α , tumour necrosis factor alpha; IL-4, interleukin 4; IgG1, immunoglobulin G1; MHC, major histocompatibility complex; hEcad, humanized epithelial cadherin; *L. lactis*, *Lactococcus lactis*; *L. monocytogenes*, *Listeria monocytogenes*; Lm, *Listeria monocytogenes*; ILO, ivanolysin O; *thyA*, thymidylate synthase A

Submitted: 08/26/09

Revised: 10/07/09

Accepted: 10/23/09

Previously published online:
www.landesbioscience.com/journals/biobugs/article/10408

*Correspondence to:
Jim O' Mahony; Email: Jim.OMahony@cit.ie

Mycobacterium avium subsp. *paratuberculosis* (MAP) is the etiological agent of Johne disease, a granulomatous enteritis of cattle and other domesticated and wild ruminant species. Johne disease is prevalent worldwide and has a significant impact on the global agricultural economy. Current vaccines against Johne are insufficient in stemming its spread, and associated side-effects prevent their widespread use in control programs. Effective and safe vaccine strategies are needed. The main purpose of this paper is to propose and evaluate the development of a novel oral subunit-vaccine using a patho-biotechnological approach. This novel strategy, which harnesses pathogenetic elements from the intracellular pathogen *Listeria monocytogenes*, may provide a realistic route towards developing an effective next generation subunit vaccine against Johne disease and paratuberculosis.

Introduction

Mycobacterium avium subspecies *paratuberculosis* (MAP) is a slow growing, Gram positive, acid fast, intracellular pathogenic Bacillus and the etiological agent of Johne disease in cattle. This is a chronic untreatable granulomatous enteritis with symptoms including intestinal inflammation, poor nutrient uptake, severe diarrhoea, emaciation and eventual death of the infected host.¹ Paratuberculosis infection has been demonstrated mainly in ruminants including cattle, sheep, rabbits, bison and red deer.¹⁻³

Johne disease is prevalent in cattle worldwide and as such, has a significant impact on the global economy.⁴ The U.S dairy industry alone has reported annual losses ranging from US\$200 million to 1.5 billion due to infection.^{4,5} These costs are mainly attributed to decreased milk production, weight loss and increased culling measures. In Ireland, substantial economic losses have also occurred consequent to the presence of Johne disease within dairy herds.⁶

MAP contaminates and persists in water and the environment, can survive milk pasteurisation and is present in dairy and meat products from infected animals.⁷ It is therefore inevitable that human populations are widely exposed.⁷ An overwhelming balance of probability and public health risk favours the conclusion that MAP is also pathogenic to humans.⁷ It is a strong candidate pathogen in the development of Crohn disease, a human systemic disorder involving chronic inflammation of the intestine, similar to that observed in Johne disease infected animals.^{7,8}

Vaccination Against MAP

There is currently no cure for Johne disease and hygienic measures or culling procedures are not sufficient to prevent its spread.⁹ Moreover, the available vaccines against Johne disease do not fully protect animals from infection, but rather reduce clinical symptoms and limit shedding of MAP in feces.⁹ While several whole cell vaccines have been developed, based on heat killed or live attenuated strains of MAP, issues related to their use prevents

their widespread application in control strategies.^{9,10} The associated drawbacks with these vaccines include (1) the presence of local granulomatous lesions at the site of injection, (2) interference with current serodiagnostic tests for MAP and (3) failure to fully protect animals from subsequent exposure to MAP. Administration of vaccines developed from whole organisms also increases the likelihood of interference with bovine tuberculosis screening tests.^{11,12}

Sequencing of the entire genome of MAP strain K-10 in 2005 has permitted the identification of immunodominant protein antigens, which induce strong humoral or cell mediated immune responses, for subsequent inclusion in diagnostic tests or subunit based vaccines.^{13,14} Recent subunit vaccines appear to overcome many of the issues associated with whole cell strategies but nevertheless they have failed to fully protect against MAP in experimental infection models.⁹ Huygen and Rosseels recently carried out a definitive review, entitled "Vaccination against Paratuberculosis", which describes in detail the past and current approaches to vaccine design for paratuberculosis as well as immunodominant antigens identified prior to its publication.⁹

Next generation animal vaccines will be complex molecular entities with multiple components tailored to generate the most potent and effective immune response. Accordingly, through comparative bioinformatic analysis of the completed MAP genome, a defined set of MAP genes encoding potentially immunodominant secreted, cytosolic and surface expressed antigens have been assembled within our laboratory. The challenge ahead is to effectively deliver these antigens in a manner that will stimulate the appropriate immune responses, a task which will require an efficient and controllable vaccine strategy. Building on the experience of previous vaccine strategies will be crucial.

Vaccine developments against other intracellular pathogens, similar to MAP, have used attenuated strains of the intracellular pathogen *L. monocytogenes* as effective vaccine carriers to the immune system.¹⁵ These strategies are based on observations that the pathogen has both

a phagosomal and cytosolic phase, facilitating the stimulation of CD4⁺ and CD8⁺ immune responses respectively.^{15,16} The infection strategy of *L. monocytogenes* has notable similarities to that employed by MAP but despite this, its potential as a MAP vaccine carrier has not been investigated. It is likely that this is due to concerns over the use of attenuated pathogens in vaccine development which comes with the possibility of reversion to a virulent phenotype.¹⁷

Alternatively, probiotic or GRAS (generally regarded as safe) bacterial strains have also been assessed for applications in vaccine delivery strategies.^{18,19} In this field however, their potential is hampered by fragility and sensitivity toward stresses associated with formulation and environmental conditions in the gut including the presence of bile, high osmolarity, low iron or acidic environments.²⁰ The advent of patho-biotechnology, which exploits inherent mechanisms from pathogenic bacteria, has brought about novel strategies to improve the potential of these probiotic or GRAS strains for use in clinical, drug, and vaccine delivery applications.^{17,21}

The main purpose of this review is to propose and evaluate the development of a novel oral subunit-vaccine against MAP and Johne disease which will utilize a patho-biotechnological approach. A *Lactobacillus* strain with GRAS status, harbouring an inducible expression vector encoding immunodominant MAP antigens, is to be equipped with patho-genetic elements derived from *L. monocytogenes* which will allow the strain to access appropriate antigen presentation pathways in order to stimulate a strong immune response. After vaccination with MAP antigens via this novel delivery platform, levels of protective efficacy will be assessed in a murine model of infection.

A successful vaccine strategy against Johne disease will require a detailed understanding of the causative agent, its mode of transmission and the associated host immune responses. The following sections will attempt to describe these aspects of MAP infection while simultaneously comparing *L. monocytogenes* infection, to illustrate their combined potential as part of a patho-biotechnological approach to vaccine design for

Johne disease. The patho-biotechnological methodologies which have led to the present vaccine development will be discussed. The biological containment strategies to prevent the dissemination and proliferation of the vaccine strain within the environment are also outlined.

***Mycobacterium avium* Subspecies *paratuberculosis* (MAP)**

MAP is shed in the feces of infected animals and can survive within the environment for up to 12 months.²² Subsequently, planktonic cells may form biofilms or biofilm-like structures which could play a role in its prolonged survival, allowing the pathogen to spread horizontally to naive hosts via the fecal oral route.²³ Infant calves with immature immune responses are also particularly susceptible to infection via contaminated milk or colostrum on farms with a high prevalence of the disease.²⁴

Intracellular Pathogenesis

Infection with MAP takes place through the intestinal mucosa. The bacterium preferentially targets M cells present in the follicle associated epithelium (FAE) covering the continuous Peyer patches in the distal ileum of cattle.²⁵⁻²⁷ M cells are specialised epithelial cells which can deliver samples of foreign materials via trans-epithelial vesicular transport to intraepithelial lymphoid cells and macrophage, eliciting an immune response.²⁸ This ability to transport particles across the epithelial barrier is exploited by MAP, as well as other pathogens, to facilitate entry into the host.²⁹

The preferential targeting of M cells has been linked to the high expression of cell adhesion proteins called integrins on their luminal surface, unlike other intestinal epithelial cells.²⁹ In one study it was shown that MAP Fibronectin Attachment Protein (FAP) present on the bacterium surface forms a fibronectin bridge with these integrins on the M cells and mediates invasion of the pathogen.²⁷ However, disruption of fibronectin binding did not completely inhibit invasion of M cells indicating a fibronectin-independent mechanisms of invasion.²⁷ MAP is not restricted to this portal of entry as it has

been shown to enter the small intestine of kid goats in areas without Peyer patches via enterocyte-like cells.²⁵

A MAP oxidoreductase gene (MAP 3464) was recently linked to invasion of bovine epithelial cells through the transport and folding of a MAP surface protein (MAP3985c) related to the activation of the host cell Cdc42 trigger mechanism involving cytoskeletal rearrangement and bacterial engulfment.²⁶ In this case, the MAP3464 gene product was found to be upregulated upon exposure to an MDBK epithelial cell line and was linked to invasion as a mutant MAP strain, Δ Ox, was incapable of expressing the surface protein and showed a reduced invasive ability compared to the wildtype strain.²⁶

In contrast to this “trigger” mechanism used by MAP, *L. monocytogenes* entry to these non-phagocytic cells is mediated by a so called “zipper” mechanism characterized by intimate interaction between the pathogen and the host cell membrane leading to progressive engulfment of the bacterium.³⁰ The listerial surface protein internalin A (inlA) is involved in this attachment to, and subsequent entry of, epithelial cells which express its specific receptor, E-cadherin.³¹ Consequently it is feasible that a GRAS (or indeed) probiotic vaccine strain equipped with this mechanism from *L. monocytogenes* could pass the mucosal barrier and access subepithelial immune cells of the host.

After gaining access to the subepithelial layer of the intestinal mucosa MAP is phagocytosed by subepithelial macrophages.³² Once inside, the pathogen is capable of evading or misdirecting the normal killing mechanism of macrophage aimed toward clearing infection.³³ One study demonstrated that within bovine monocytes MAP elicited only modest production of reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI). Also, when compared to ingested heat-killed MAP, which displayed 94% co-localization with lysosomes, viable bacilli were able to inhibit phagolysosome fusion resulting in a reduction to 30% co-localization. The same study indicated that simultaneous intracellular multiplication and killing of MAP occurs within the phagosome.³⁴

L. monocytogenes within murine macrophage displays a similar pattern of concomitant killing and intracellular multiplication but unlike MAP is unable to prevent colocalization with lysosomes. Instead, the successful intracellular survival of *L. monocytogenes* is related to escape from the acidified phagosomal compartment before phagolysosome fusion has occurred.³⁵ The escape is mediated by a unique cytolysin which targets the phagosomal membrane, listeriolysin O (LLO), which is encoded by the *hly* gene.³⁶ LLO represents a second patho-genetic element from *L. monocytogenes* which could potentially be included in a recombinant MAP vaccine delivery strain.

Immune Responses to MAP and the Causation of Johne Disease

The principal goal of vaccination is to prime the immune system to facilitate a more effective and rapid immune response following infection with the pathogen, therefore understanding the interactions between the pathogen and the immune system are fundamental in the development of an effective vaccine. Paratuberculosis and Johne disease in cattle can be categorized into three distinct stages of disease or infection: (1) early infection, (2) subclinical infection and (3) clinical infection.³⁷

Herein, we briefly describe the immune responses of the host in order to explicate the pathogenesis of MAP in cattle and demonstrate the criteria necessary for effective vaccination strategies. For an in-depth analysis of the interactions between MAP and the host immune system, the reader is referred to previous reviews of particular interest.^{37,38}

MAP is an intracellular pathogen and therefore the cellular immune response plays a key role in its control within the host.^{37,39} The cellular immune response is comprised of both T helper lymphocytes (CD4⁺) and cytolytic T lymphocytes (CTL) or killer T lymphocytes (CD8⁺).⁴⁰ T helper cells are responsible for orchestrating and directing responses, whereas CTLs are the killer cells that traffic to the site of infection and lyse infected cells.⁴⁰ Activated CD4⁺ cells can differentiate into T helper 1 (Th1) cells, which secrete

proinflammatory cytokines (IFN γ and TNF α), or T helper 2 (Th2) cells, which secrete anti-inflammatory cytokines (IL-4, 5, 10 and 13).⁴⁰ Th1 T cells are involved in effective immune responses to intracellular pathogens by promoting microbicidal activities of macrophages. Th2 T cells promote immunoglobulin G₁ (IgG1) antibody production, suppression of Th1 activity, and are likely ineffective in case of intracellular infections.³⁹

Early infection. It is generally regarded that cell mediated immune responses dominate during early stages of the Johne’ disease and are vital for control of infection.⁴¹ Within the macrophage phagosome, a small proportion of MAP are lysed resulting in the presentation of antigens through the MHC class II pathway, which in turn stimulates CD4⁺ T cells and IFN γ production³⁴ (see Fig. 1A–C). IFN γ is an important cytokine involved in recruitment and activation of naive macrophages, nonetheless production of IFN γ does little to cure persistently infected macrophages.³⁸ The immune system must elicit a strong CD8⁺ cytolytic response if it is to clear these macrophages.³⁷ Stimulation of CD8⁺ T cells requires antigen presentation through the MHC class I pathway which necessitates the presence of antigens in the cytosolic region, as opposed to the phagosome where MAP resides.³⁴

It has previously been demonstrated that secreted mycobacterial proteins (of up to 70 kDa in size) may freely pass into the macrophage cytoplasm. Thus MAP antigens secreted into the phagosome may escape into the cytosol and after transportation across the endoplasmic reticulum they are available for presentation via the MHC I pathway,^{42,43} (see Fig. 1D and E). One study, in support of this, demonstrated that MAP was capable of secreting a functional low molecular weight tyrosine phosphatase into the macrophage cytoplasm which is suspected of mediating interaction with host cell substrates and interference with pathways necessary for killing the engulfed bacteria.⁴⁴

Maintenance of a Th1-type immune response during the early stages of infection is vital for myco-bacteriostasis.³⁷ Failure to elicit a strong enough CD8⁺ response to effectively clear infection

Figure 1. *Mycobacterium avium paratuberculosis* within macrophage. MAP infects by passing the mucosal barrier, preferentially via M cells, and after which it is engulfed by subepithelial macrophage (A). A number of MAP bacilli are degraded within the phagosome (B) and stimulate CD4⁺ immune responses via antigen presentation through the MHC class II pathway. (C) Alternatively MAP evades destruction within phagosome, through inhibition of normal killing mechanisms, and proliferates. (D) Secreted MAP proteins may pass from the phagosome to the cytosol and be subsequently available for presentation to CD8⁺ immune responses via the MHC class I pathway. Survival and proliferation within macrophage is a vital element in the virulence of paratuberculosis.

results in increased tissue damage to intestinal epithelial cells (due to prolonged exposure to high levels of proinflammatory cytokines) along with an increase in bacterial loads, both of which are characteristic of subclinical infection.³⁷

Subclinical infection. The subclinical stage of the disease can last for 2–5 years with the host presenting no clinical signs of disease, however, due to intermittent shedding in feces, MAP may be detected by fecal culture.^{9,33}

Granuloma formation is an important characteristic of the subclinical phase of MAP infection and serves to sequester persistently infected macrophage to prevent pathogen spread to adjacent cells.⁴⁵ However, it also allows for almost unrestricted pathogen proliferation as well as providing partial protection from newly recruited CTLs. The lysis of infected macrophage by increasing levels of toxic intermediates (ROI and RNI) or CTLs causes sporadic release of MAP from granulomas

and the spread of disease along the intestinal tract.³⁷

Clinical infection. During the clinical stage of Johne disease numerous granulomas result in significant damage to the host's intestinal tract, with eventual loss of mucosal function. The animal may suffer from intermittent or persistent diarrhoea and sheds high levels of MAP into the environment. Mycobacterial-specific Th-1 immune responses are low during this stage and are replaced by non protective Th-2 responses where animals may present high antibody levels against MAP.⁹ Animals with overt infection are usually culled from the herd immediately on detection.⁴⁶

Implications for an Effective MAP Vaccine

The necessity for a strong cellular Th-1 type immune response at the early stages of Johne disease, characterized by the

presence of CD4⁺ T lymphocytes to control, and cytolytic CD8⁺ T lymphocytes to effectively clear the infection, has profound implications on vaccine development. A successful vaccine will require strong stimulation of both these lymphocyte subsets to induce a sufficient immunological memory which, upon challenge with MAP, can respond quickly and efficaciously.

As already mentioned *L. monocytogenes* displays a pattern of concomitant killing and intracellular multiplication within murine macrophage.³⁵ This facilitates the stimulation of both the CD4⁺ T-cell immune response (through cell destruction within the phagosome and MHC class II antigen presentation) and the CD8⁺ T-cell response (through multiplication within the intracytoplasmic environment and antigen presentation to the MHC class I pathway)^{1,16} (see Fig. 2). Both *L. monocytogenes* and MAP stimulate the production of IFN γ , as well as various other

Figure 2. Infectious life cycle of *L. monocytogenes* (adapted from Sleator and Hill). *Listeria* has the ability to cross the epithelial barrier, through the expression of internalins (inlA, inlB), and after which be engulfed by sub-epithelial macrophage (A). While in the phagosome a number of cells are lysed (B) releasing antigens for subsequent presentation through the MHC class II pathway to stimulate CD4⁺ immune responses (C). Alternatively, *Listeria* escapes the phagosome using a pore forming cytolysin called listeriolysin O (D). Within the cytosol, Listerial proteins may be processed via the MHC class I pathway for stimulation of CD8⁺ immune responses (E). *Listeria* may also pass to neighboring cells through the expression of other virulence factors (F).

proinflammatory cytokines, at an early stage of their respective infection. IFN γ is considered vital in the development of Th1-dependant acquired resistance against both of these intracellular pathogens.^{9,36}

Attenuated strains of *Listeria monocytogenes* have previously been assessed as vaccine delivery vehicles for other intracellular pathogens, including *Francisella tularensis* (the causative agent of Tularemia), and have shown promising results.¹⁵ Taking this into consideration, along with the aforementioned similarities in pathogenesis, an attenuated *L. monocytogenes* strain would appear a potentially effective delivery vehicle in a vaccine strategy against MAP. Despite this potential, no research has been published indicating such a strategy. It is possible that this is due to concerns over the use of attenuated pathogens for vaccination, which comes with the ever present possibility of reversion to a virulent phenotype.¹⁷

An intriguing alternative to using attenuated pathogens has arisen from the application of a patho-biotechnological approach to vaccine development, exploiting the potential of pathogens, but through the use of probiotic or GRAS bacterial strains.

Patho-Biotechnology

Patho-biotechnology is a term originally used by Sleator and Hill¹⁷ which describes the application of pathogen derived stress survival mechanisms for the design of more robust and effective probiotic cultures with improved efficacy in clinical applications, vaccine development and drug delivery platforms.^{17,20}

A number of health-promoting lactic acid bacteria are currently used in clinical contexts. However, the full therapeutic potential of these probiotic bacteria is not realized as a result of their susceptibility

to stresses ever present in mammalian gut such as bile, high osmolarity, low iron or acidic environments.^{20,21} Conversely, pathogenic bacteria have evolved numerous virulence mechanisms which allow them to successfully invade, persist and spread throughout a host while evading its immune responses as well as surviving for prolonged periods within the environment.¹⁷ Widespread access to whole genome sequences of many pathogenic and non-pathogenic bacteria has made it possible to elucidate the genetic elements which confer these mechanisms to pathogenic strains. Subsequent application of such genetic elements to fragile probiotic strains has permitted the development of recombinant or "designer" probiotics which are sturdier and have improved tolerance to stresses.²⁰ At the forefront of patho-biotechnology, *L. monocytogenes* has become an important source of pathogenetic elements which are being applied

to probiotic strains to improve their clinical efficacy and survival under stresses.

A Patho-Biotechnological Approach Towards Developing an Effective MAP Vaccine

Herein, we propose the development of a novel oral probiotic vaccine platform capable of expressing immunodominant MAP antigens to subepithelial macrophage thus eliciting a strong cell mediated immune against MAP using a patho-biotechnology based approach.

After oral ingestion the first listerial element, internalin A (*inlA*), will enable the *Lactobacillus* strain to traverse the gut wall and be engulfed by subepithelial macrophage. The second patho-genetic element, listeriolysin O (LLO), will promote escape from the phagosome and allow expression and secretion of the MAP antigens to the macrophage cytosol. While in the phagosome a certain proportion of *Lactobacillus* cells will be lysed releasing antigens for subsequent processing and presentation to the MHC class II pathway stimulating a strong CD4⁺ T-cell response. Antigens secreted within the cytosol will be processed and presented to the MHC class I pathway for stimulation of a CD8⁺ T-cell response. Presentation in such a manner, and the stimulation of a strong cell mediated immune response, should induce an immunological memory and provide protection against a subsequent MAP challenge in an animal model of infection (see Fig. 3).

The rationale behind the application of both patho-genetic elements to the *Lactobacillus* delivery platform is discussed in greater detail below:

Internalin A. As previously mentioned, internalin A (*inlA*) is normally used by *L. monocytogenes* to gain entry into mammalian intestinal epithelial cells and is critical to its pathogenicity.³⁰ In 1997, Lecuit et al. demonstrated that expression of *inlA* was sufficient to promote internalisation of a non invasive enterococci, as well as inert particles in the form of protein coated latex beads, into cells expressing its receptor E-cadherin (Ecad).³⁰ The interaction between InlA and E-cadherin is species specific, and although human and ruminant E-cadherin will interact

with InlA, murine E-cadherin does not.⁴⁷ As the planned development will utilise a murine model of vaccination and experimental infection, it is our intention to use a transgenic murine line, which express humanized E-cadherin (hEcad), in the initial vaccine trials. This approach is made feasible by the fact that Lecuit et al. demonstrated that transgenic mice expressing humanized E-cadherin (hEcad) solely in enterocytes successfully interact with InlA allowing entry of *L. monocytogenes* to the target cells.⁴⁸

Another study, aimed at developing a DNA vaccine delivery strain, demonstrated that a *Lactococcus lactis* strain expressing *inlA* successfully entered intestinal cells in vivo after oral inoculation of Guinea pigs, although once internalised it was rapidly destroyed. The authors suggested that while the *L. lactis inlA*⁺ strain did not persist for long enough to induce a systemic immune response, further cloning of listeriolysin O (LLO) from *L. monocytogenes* would potentially increase the persistence of the recombinant strain and allow release of the *L. lactis* DNA content into the cytosol of host cells.⁴⁹

Listeriolysin O. A 2008 study by Bahey-El-Din et al. demonstrated that a *L. lactis* strain expressing listeriolysin O, when delivered via intraperitoneal injection to a murine host, was capable of secreting prolonged high levels of LLO after induction and conferred protective immunity against subsequent *L. monocytogenes* infection.⁵⁰ Importantly the authors observed that an LLO-expressing *L. lactis* strain may have the potential to act as a platform for directing other co-expressed antigens towards the cytosolic MHC class I pathway for enhanced stimulation of the CD8⁺ T-cell response.

The LLO molecule itself is also a potent antigen considered to mediate a strong Th-1 type response categorized by high levels of IFN γ production.³⁶ It has been shown that LLO is capable of inhibiting Th2 immune responses by skewing differentiation of antigen specific T-cells into Th1 cells.⁵¹

Stimulation of IFN γ and Th-1 type responses are widely regarded as a necessity in protection against MAP.⁵² Therefore, the incorporation of LLO within the present vaccine will not only permit entry to

the macrophage cytosol allowing presentation of antigens to CD8⁺ T cells, but may also act as an adjuvant to these antigens increasing the potency of the Th-1 type responses.

In contrast to the adjuvant activity of listeriolysin O (LLO) we also present an alternate strategy to be carried simultaneously, without the aid of the adjuvant, which should provide a more silent background for improved evaluation of the antigens immunostimulatory abilities.

The ruminant pathogen *Listeria ivanovii* secretes ivanolysin O (ILO), a cytolyisin encoded by the *ilo* gene, which shares 80% homology in amino acid sequence to *L. monocytogenes* listeriolysin O (LLO).⁵³ One study, using a LLO deficient strain of *L. monocytogenes* expressing ILO under the control of the original *hly* promoter, demonstrated that ILO can functionally replace LLO in vitro for efficient phagosomal escape and intracellular multiplication. Intracellular multiplication of the ILO-expressing strain was essentially indistinguishable from that of the LLO-expressing strain.⁵³ A separate study showed that the level of IFN γ induced by a *Lm ILO*⁺ strain was significantly lower (but not null), both in vitro and in vivo, than a *Lm LLO*⁺ strain which was highly capable of inducing IFN γ . It was suggested that some structural differences between ILO and LLO possibly gave rise to the difference in level of IFN γ inducing ability.³⁶

When examined along with the current LLO⁺ MAP vaccine strain, a recombinant probiotic delivery platform expressing the same MAP antigens but equipped with ILO should provide valuable insights into the levels of adjuvant-like activity induced by listeriolysin (LLO) as well as giving a clearer indication of the immune responses generated to these antigens individually.

Biological Containment

The use of genetically modified organisms in veterinary medicine raises legitimate concerns about their survival and propagation in the environment and about the dissemination of antibiotic markers or other genetic modifications to other microorganisms.²⁰ Biological containment systems can be subdivided into active and passive forms. Active containment

Figure 3. Novel patho-biotechnological vaccine development against Johne disease. A *Lactobacillus* strain, harbouring an expression vector encoding MAP antigens, will be equipped with an internalin from *Listeria* which will allow translocation across the epithelial barrier and subsequent phagocytosis by macrophages (A). In a similar manner to *Listeria* within the phagosome, a number of lactobacilli will be lysed allowing presentation of the expressed MAP antigens via the MHC class II pathway to stimulate strong CD4⁺ immune responses (B and C). Heterologously expressed listeriolysin O, from *Listeria monocytogenes*, will allow the *Lactobacillus* strain to escape the phagosome. (D) Expression of MAP antigens within the macrophage cytosol will stimulate strong CD8⁺ immune responses through the MHC class I pathway (E).

provides control through the conditional production of a compound which is toxic to the cells. Passive containment on the other hand is dependent on complementation of an auxotrophy by supplementation with either an intact gene or essential metabolite.^{20,54}

We propose to address the issue of biological containment by creating conditional auxotrophic mutants of the *Lactobacillus* delivery strain. One of the potential targets is the thymidylate synthase (*thyA*) gene which is essential for growth; mutant strains only growing in the presence of added thymidine or thymine.⁵⁵

The choice of *thyA* as a target gene combines the advantages of passive and active containment systems. Thymine auxotrophy involves activation of the SOS repair system and DNA fragmentation, thereby constituting an indigenous suicide system. Thymine and thymidine growth dependence differs from most other

auxotrophies in that absence of the essential component is bactericidal in the former and bacteriostatic in the latter. Thus, *thyA*-deficient bacteria cannot accumulate in the environment.²⁰ As previously outlined for *L. lactis* we propose to replace the *thyA* gene with a transgene (Internalin A or listeriolysin O) by double crossover using a conditionally non-replicative plasmid.⁵⁶

This approach addresses bio-safety concerns on a number of levels. Firstly, no resistance marker is required to guarantee stable inheritance of the transgene, thus overcoming any potential problems associated with dissemination of antibiotic resistance. Second, accumulation of the genetically modified organism in the environment is highly unlikely given that rapid death occurs upon thymidine starvation.⁵⁷ Finally should an intact *thyA* be acquired from closely related bacteria by means of homologous recombination then the transgene would be lost.

Conclusion

Examination of the complex interactions between MAP and host's immune system, the issues associated with current vaccines and the criteria generally regarded as necessary for protective immunity, has led to current proposal of a novel patho-biotechnological vaccination strategy against Johne disease. This novel vaccine consists of a *Lactobacillus* delivery strain with GRAS status harbouring an inducible expression vector, encoding immunodominant MAP antigens, and equipped with two patho-genetic mechanisms from the intracellular *Listeria monocytogenes* to enable access to subepithelial macrophages phagosomal and cytosolic compartments. Antigen presentation in this manner will stimulate both CD4⁺ and CD8⁺ T lymphocyte subsets evoking a cell mediated immune response. The protective efficacy of the selected MAP antigens as well as

the effectiveness of the patho-biotechnological delivery strain will be assessed in a murine model of infection. If successful, the current vaccine development may mark a significant breakthrough in the control of Johne disease.

Acknowledgements

The author's acknowledge the financial assistance of the Irish Government through funding by a Food Institutional Research Measure (FIRM) grant.

References

- Chacon O, Bermudez LE, Barletta RG. Johne's disease, inflammatory bowel disease, and *Mycobacterium paratuberculosis*. *Annu Rev Microbiol* 2004; 58:329-63.
- Sohal JS, Singh SV, Singh PK, Singh AV. On the evolution of 'Indian Bison type' strains of *Mycobacterium avium* subspecies *paratuberculosis*. *Microbiol Res* 2010;165:163-71.
- Sleeman JM, Manning EJ, Rohm JH, Sims JP, Sanchez S, Gerhold RW, et al. Johne's disease in a free-ranging white-tailed deer from Virginia and subsequent surveillance for *Mycobacterium avium* subspecies *paratuberculosis*. *J Wildl Dis* 2009; 45:201-6.
- Harris NB, Barletta RG. *Mycobacterium avium* subsp. *paratuberculosis* in Veterinary Medicine. *Clin Microbiol Rev* 2001; 14:489-512.
- Ott SL, Wells SJ, Wagner BA. Herd-level economic losses associated with Johne's disease on US dairy operations. *Prev Vet Med* 1999; 40:179-92.
- Barrett D, Good M, Hayes M, More SJ. The economic impact of Johne's disease in an Irish dairy herd: A case study. *Irish Vet J* 2006; 59:282-8.
- Hermon-Taylor J. *Mycobacterium avium* subspecies *paratuberculosis*, Crohn's disease and the Doodson scenario. *Gut Pathog* 2009; 1:15.
- Scanu AM, Bull TJ, Cannas S, Sanderson JD, Sechi LA, Dettori G, et al. *Mycobacterium avium* subspecies *paratuberculosis* infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities. *J Clin Microbiol* 2007; 45:3883-90.
- Rosseels V, Huygen K. Vaccination against paratuberculosis. *Expert Rev Vaccines* 2008; 7:817-32.
- Collins MT. Clinical approach to control of bovine paratuberculosis. *J Am Vet Med Assoc* 1994; 204:208-10.
- Nedrow AJ, Gavalchin J, Smith MC, Stehman SM, Maul JK, McDonough SP, et al. Antibody and skin-test responses of sheep vaccinated against Johne's Disease. *Vet Immunol Immunopathol* 2007; 116:109-12.
- Mackintosh CG, Labes RE, Thompson BR, Clark RG, de Lisle GW, Johnstone PD, et al. Efficacy, immune responses and side-effects of vaccines against Johne's disease in young red deer (*Cervus elaphus*) experimentally challenged with *Mycobacterium avium* subsp. *paratuberculosis*. *N Z Vet J* 2008; 56:1-9.
- Li L, Bannantine JP, Zhang Q, Amonsin A, May BJ, Alt D, et al. The complete genome sequence of *Mycobacterium avium* subspecies *paratuberculosis*. *Proc Natl Acad Sci USA* 2005; 102:12344-9.
- Santema W, Overdijk M, Barends J, Krijgsveld J, Rutten V, Koets A. Searching for proteins of *Mycobacterium avium* subspecies *paratuberculosis* with diagnostic potential by comparative qualitative proteomic analysis of mycobacterial tuberculin. *Vet Microbiol* 2009; 138:191-6.
- Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. Recombinant attenuated *Listeria monocytogenes* vaccine expressing *Francisella tularensis* IgLC induces protection in mice against aerosolized Type A *F. tularensis*. *Vaccine* 2009; 27:1216-29.
- Starks H, Bruhn KW, Shen H, Barry RA, Dubensky TW, Brockstedt D, et al. *Listeria monocytogenes* as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. *J Immunol* 2004; 173:420-7.
- Sleator RD, Hill C. 'Bioengineered Bugs'—a patho-biotechnology approach to probiotic research and applications. *Med Hypotheses* 2008; 70:167-9.
- Pouwels PH, Leer RJ, Shaw M, Heijne den Bak-Glashouwer MJ, Tielens FD, Smit E, et al. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. *Int J Food Microbiol* 1998; 41:155-67.
- Shi D, Song Y, Li YJ. Progress on *Lactococcus lactis* expressing heterologous antigens as live mucosal vaccines. *Wei Sheng Wu Xue Bao* 2006; 46:680-3.
- Sleator RD, Hill C. Improving probiotic function using a pathobiotechnology approach. *Gene Ther Mol Biol* 2007; 11:269-74.
- Sleator RD, Hill C. New frontiers in probiotic research. *Lett Appl Microbiol* 2008; 46:143-7.
- Whittington RJ, Marshall DJ, Nicholls PJ, Marsh IB, Reddacliff LA. Survival and dormancy of *Mycobacterium avium* subsp. *paratuberculosis* in the environment. *Appl Environ Microbiol* 2004; 70:2989-3004.
- Wu CW, Schmoller SK, Bannantine JP, Eckstein TM, Inamine JM, Livesey M, et al. A novel cell wall lipopeptide is important for biofilm formation and pathogenicity of *Mycobacterium avium* subspecies *paratuberculosis*. *Microb Pathog* 2009; 46:222-30.
- Baptista FM, Nielsen SS, Toft N. Association between the presence of antibodies to *Mycobacterium avium* subspecies *paratuberculosis* and somatic cell count. *J Dairy Sci* 2008; 91:109-18.
- Sigurdardóttir OG, Bakke-McKellep AM, Dønne B, Evensen O. *Mycobacterium avium* subsp. *paratuberculosis* enters the small intestinal mucosa of goat kids in areas with and without Peyer's patches as demonstrated with the everted sleeve method. *Comp Immunol Microbiol Infect Dis* 2005; 28:223-30.
- Alonso-Hearn M, Patel D, Danelishvili L, Meunier-Goddik L, Bermudez LE. The *Mycobacterium avium* subsp. *paratuberculosis* MAP3464 gene encodes an oxidoreductase involved in invasion of bovine epithelial cells through the activation of host cell Cdc42. *Infect Immun* 2008; 76:170-8.
- Secott TE, Lin TL, Wu CC. *Mycobacterium avium* subsp. *paratuberculosis* fibronectin attachment protein facilitates M-cell targeting and invasion through a fibronectin bridge with host integrins. *Infect Immun* 2004; 72:3724-32.
- Neutra MR. Current concepts in mucosal immunity. V Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. *Am J Physiol* 1998; 274:785-91.
- Sansonetti PJ, Phalipon A. M cells as ports of entry for enteroinvasive pathogens: mechanisms of interaction, consequences for the disease process. *Semin Immunol* 1999; 11:193-203.
- Lecuit M, Ohayon H, Braun L, Mengaud J, Cossart P. Internalin of *Listeria monocytogenes* with an intact leucine-rich repeat region is sufficient to promote internalization. *Infect Immun* 1997; 65:5309-19.
- Mengaud J, Ohayon H, Gounon P, Mege R-M, Cossart P. E-cadherin is the receptor for internalin, a surface protein required for entry of *L. monocytogenes* into epithelial cells. *Cell* 1996; 84:923-32.
- Momotani E, Whipple DL, Thiermann AB, Cheville NF. Role of M cells and macrophages in the entrance of *Mycobacterium paratuberculosis* into domes of ileal Peyer's patches in calves. *Vet Pathol* 1988; 25:131-7.
- Basler T, Geffers R, Weiss S, Valentin-Weigand P, Goethe R. *Mycobacterium avium* subspecies induce differential expression of pro-inflammatory mediators in a murine macrophage model: evidence for enhanced pathogenicity of *Mycobacterium avium* subspecies *paratuberculosis*. *Immunobiology* 2008; 213:879-88.
- Woo SR, Heintz JA, Albrecht R, Barletta RG, Czuprynski CJ. Life and death in bovine monocytes: the fate of *Mycobacterium avium* subsp. *paratuberculosis*. *Microb Pathog* 2007; 43:106-13.
- de Chastellier C, Berche P. Fate of *Listeria monocytogenes* in murine macrophages: evidence for simultaneous killing and survival of intracellular bacteria. *Infect Immun* 1994; 62:543-53.
- Hara H, Kawamura I, Nomura T, Tominaga T, Tsuchiya K, Mitsuyama M. Cytolysin-dependent escape of the bacterium from the phagosome is required but not sufficient for induction of the Th1 immune response against *Listeria monocytogenes* infection: distinct role of Listeriolysin O determined by cytolysin gene replacement. *Infect Immun* 2007; 75:3791-801.
- Coussens PM. *Mycobacterium paratuberculosis* and the bovine immune system. *Anim Health Res Rev* 2001; 2:141-61.
- Sohal JS, Singh SV, Tyagi P, Subhodh S, Singh PK, Singh AV, et al. Immunology of mycobacterial infections: with special reference to *Mycobacterium avium* subspecies *paratuberculosis*. *Immunobiology* 2008; 213:585-98.
- Koets A, Rutten V, Hoek A, van Mil F, Müller K, Bakker D, et al. Progressive bovine paratuberculosis is associated with local loss of CD4(+) T cells, increased frequency of gamma delta T cells, and related changes in T-cell function. *Infect Immun* 2002; 70:3856-64.
- Esser MT, Marchese RD, Kierstead LS, Tussey LG, Wang F, Chirmule N, et al. Memory T cells and vaccines. *Vaccine* 2003; 21:419-30.
- Bannantine JP, Bayles DO, Waters WR, Palmer MV, Stabel JR, Paustian ML. Early antibody response against *Mycobacterium avium* subspecies *paratuberculosis* antigens in subclinical cattle. *Proteome Sci* 2008; 28:5-6.
- Teitelbaum R, Cammer M, Maitland ML, Freitag NE, Condeelis JS, Bloom BR. Mycobacterial infection of macrophages results in membrane-permeable phagosomes. *Proc Natl Acad Sci USA* 1999; 96:15190-5.
- Lilenbaum W, Marassi CD, Oelemann WMR. Paratuberculosis: an update. *Braz J Microbiol* 2007; 38:580-90.
- Bach H, Sun J, Hmama Z, Av-Gay Y. *Mycobacterium avium* subsp. *paratuberculosis* PtpA is an endogenous tyrosine phosphatase secreted during infection. *Infect Immun* 2006; 74:6540-6.
- Lei L, Plattner BL, Hostetter JM. Live *Mycobacterium avium* subsp. *paratuberculosis* and a killed-bacterium vaccine induce distinct subcutaneous granulomas, with unique cellular and cytokine profiles. *Clin Vaccine Immunol* 2008; 15:783-93.
- Whitlock RH, Buerget C. Preclinical and clinical manifestations of paratuberculosis (including pathology). *Vet Clin North Am Food Anim Pract* 1996; 12:345-56.
- Lecuit M, Dramsi S, Gottardi C, Fedor-Chaiken M, Gumbiner B, Cossart P. A single amino acid in E-cadherin responsible for host specificity towards the human pathogen *Listeria monocytogenes*. *EMBO J* 1999; 18:3956-63.
- Lecuit M, Vandormael-Pournin S, Lefort J, Huerre M, Gounon P, Dupuy C, et al. A transgenic model for listeriosis: role of internalin in crossing the intestinal barrier. *Science* 2001; 292:1722-5.

49. Guimarães VD, Gabriel JE, Lefèvre F, Cabanes D, Gruss A, Cossart P, et al. Internalin-expressing *Lactococcus lactis* is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. *Microbes Infect* 2005; 7:836-44.
50. Bahey-El-Din M, Casey PG, Griffin BT, Gahan CG. *Lactococcus lactis*-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against *Listeria monocytogenes* in the murine infection model. *Vaccine* 2008; 26:5304-14.
51. Yamamoto K, Kawamura I, Tominaga T, Nomura T, Kohda C, Ito J, et al. Listeriolysin O, a cytolysin derived from *Listeria monocytogenes*, inhibits generation of ovalbumin-specific Th2 immune response by skewing maturation of antigen-specific T cells into Th1 cells. *Clin Exp Immunol* 2005; 142:268-74.
52. Stabel JR. Transitions in immune responses to *Mycobacterium paratuberculosis*. *Vet Microbiol* 2000; 77:465-73.
53. Frehel C, Lety MA, Autret N, Beretti JL, Berche P, Charbit A. Capacity of ivanolysin O to replace listeriolysin O in phagosomal escape and in vivo survival of *Listeria monocytogenes*. *Microbiology* 2003; 149:611-20.
54. Steidler L, Rottiers P. Therapeutic drug delivery by genetically modified *Lactococcus lactis*. *Ann N Y Acad Sci* 2006; 1072:176-86.
55. Steidler L. Genetically engineered probiotics. *Best Prac Res Clinical Ga* 2003; 17:861-76.
56. Steidler L, Neiryck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified *Lactococcus lactis* for intestinal delivery of human interleukin 10. *Nat Biotechnol* 2003; 21:785-9.
57. Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. *Annu Rev Microbiol* 1998; 52:591-625.